Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.73 |
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | KRAS | P01116 | 9/20 | 0.66 |
| ▸ | HINT1 | P49773 | 1/20 | 0.63 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.61 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.60 |
| ▸ | GSK3A | P49840 | 2/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28443133 | 0.89 | NT5E (0.76) | NT5ETGM2KRASHINT1IMPDH2 | |
| SCHEMBL27315610 | 0.89 | NT5E (0.76) | NT5ETGM2KRASHINT1IMPDH2 | |
| SCHEMBL27688115 | 0.88 | NT5E (0.77) | NT5ETGM2KRASHINT1IMPDH2 | |
| E626 SCHEMBL18763818 | 0.88 | NT5E (0.83) | NT5ETGM2KRASHINT1IMPDH2 | |
| E626 SCHEMBL21163348 | 0.88 | NT5E (0.83) | NT5ETGM2KRASHINT1IMPDH2 | |
| E626 SCHEMBL18785103 | 0.88 | NT5E (0.83) | NT5ETGM2KRASHINT1IMPDH2 | |
| E626 SCHEMBL21803790 | 0.88 | NT5E (0.83) | NT5ETGM2KRASHINT1IMPDH2 | |
| E626 SCHEMBL20677331 | 0.88 | NT5E (0.83) | NT5ETGM2KRASHINT1IMPDH2 | |
| SCHEMBL8202050 | 0.88 | NT5E (0.83) | NT5ETGM2KRASHINT1IMPDH2 | |
| E626 SCHEMBL18759049 | 0.88 | NT5E (0.83) | NT5ETGM2KRASHINT1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812183-B | Anti-IL-36R antibodies | 勃林格殷格翰国际有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118139642-A | Compositions and methods for treating cancer | 约翰·霍普金斯大学 | 2024-06-04 | — | — | CN | disclosed |
| CN-113912717-B | EGFL 6-specific monoclonal antibodies and methods of use thereof | 得克萨斯大学体系董事会 | 2024-05-03 | — | — | CN | disclosed |
| CN-117321078-A | Administration for combination therapy with anti-CD 20/anti-CD 3 bispecific antibody and anti-CD 79B antibody drug conjugates | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-109963868-B | Antibodies, binding fragments, and methods of use | 醣基生医股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-109563170-B | anti-GITR antibodies and uses thereof | 瑞泽恩制药公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-111566120-B | 3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein | 捷克共和国有机化学与生物化学研究所 | 2023-09-29 | — | — | CN | disclosed |
| CN-111511754-B | 2'3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein | 捷克共和国有机化学与生物化学研究所 | 2023-09-12 | — | — | CN | disclosed |
| CN-116546986-A | ALK-5 inhibitors and uses thereof | 住友制药肿瘤公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-116514899-A | Prostate specific membrane antigen-antibody drug conjugates | AMBRX公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116406291-A | Administration of treatment with anti-FCRH 5/anti-CD 3 bispecific antibodies | 基因泰克公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116271117-A | CD8 imaging constructs and methods of use thereof | 伊麦吉纳博公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-108727466-B | Prostate specific membrane antigen-antibody drug conjugates | AMBRX公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-115768524-A | ILT binding agents and methods of use thereof | 恩格姆生物制药公司 | 2023-03-07 | — | — | CN | disclosed |